EBOV ssGP is a mature, recombinant Ebola Virus small Soluble Glycoprotein containing a C-terminal His-tag and is supplied as a purified protein. This protein is produced in mammalian cells and is purified by FPLC.
Formulation & Storage: Supplied in PBS and supplemented with glycerol, arginine, and glutamic acid. Store at 4°C for up to 1 week, -80°C for long term.
Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.
This antibody is intended for research use only, not for human, therapeutic, or diagnostic applications
Additional Details available upon request. Please contact products@integratedbiotherapeutics.com.
Lentivirus vector pseudotyped with Influenza H5 hemagglutinin. This pseudovirus is derived from a third-generation lentiviral vector. It is replication-incompetent, non-toxic, and must be handled under BSL-2 conditions. Infectivity and neutralization of infectivity can be measured by luciferase activity.
Formulation & Storage: Supplied in a conservation solution containing culture media with FBS. Store at -80°C, avoid freeze/thaw cycles.
Titer Estimate*: Approximatively 5 x 10^4 RLU/µL.
Usage Estimates*: Use 1 µL to obtain an RLU to background ratio of 10^3. A volume of 100 µL can be used to perform 100 reactions or 1 x 96-well plate.
Lentivirus vector pseudotyped with Influenza H7 hemagglutinin. This pseudovirus is derived from a third-generation lentiviral vector. It is replication-incompetent, non-toxic, and must be handled under BSL-2 conditions. Infectivity and neutralization of infectivity can be measured by luciferase activity.
Formulation & Storage: Supplied in a conservation solution containing culture media with FBS. Store at -80°C, avoid freeze/thaw cycles.
Titer Estimate*: Approximatively 1 x 10^5 RLU/µL
Usage Estimates*: Use 1 µL to obtain an RLU to background ratio of 10^3. A volume of 100 µL can be used to perform 100 reactions or 1 x 96-well plate.
Third-generation lentiviral vector pseudotyped with the glycoprotein from the Lassa virus strain Josiah (1976). It contains a firefly luciferase reporter system for sensitive quantification of viral entry. This pseudovirus is classified under biosafety level 2 (BSL- 2) and is not known or suspected to contain any replicative biological agents due to multiple safety modifications in the viral genome.
Formulation & Storage: Supplied in DMEM supplemented with 10% Fetal Bovine Serum.
Mouse anti-Nipah Virus Fusion protein (Nipah Virus F Protein; Nipah Virus; F Protein; NiV; NiV F Protein) is a mouse polyclonal antibody (Mouse Anti-NivF pAb) developed against the Nipah virus fusion protein F. This antibody is purified from antiserum using a Protein A column, ensuring high purity and specificity.
Immunogen/ Target: Nipah Virus Fusion Protein (Bangladesh Strain)
Formulation & Storage: Supplied in 20 mM Histidine + 150 mM NaCl + 4% Sucrose, pH 6.0. Store at +4°C for 2-3 weeks; -80°C for long-term.
Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.
This antibody is intended for research use only, not for human, therapeutic, or diagnostic applications
Mouse anti-Nipah Virus Glycoprotein (Nipah Virus G Protein; Nipah Virus; G Protein; NiV; NiV G Protein) is a mouse polyclonal antibody (Mouse Anti-NivG pAb) developed against the Nipah virus glycoprotein G. This antibody is purified from antiserum using a Protein A column, ensuring high purity and specificity.
Mouse anti-Staphylococcus aureus Amidase Polyclonal Antibody (Staphylococcus Aureus AMD Protein; Staph Virus; Amidase; AMD; Staph AMD Protein) is a mouse polyclonal antibody (Mouse Anti-AMD pAb) developed against the cell wall-modifying protein of amidase. This antibody is purified from antiserum using a Protein A column, ensuring high purity and specificity.
Mouse-Anti-VEEV-E3E2-Glycoprotein Polyclonal antibody (Venezuelan Equine Encephalitis Virus G Protein; Venezuelan Equine Encephalitis Virus; VEEV; VEEV E3E2 G Protein) is a mouse polyclonal antibody (Mouse Anti-VEEV E3E2 GP pAb) developed against the Venezuelan Equine Encephalitis Virus E3E2 Glycoprotein (GP). This antibody is purified from antiserum using a Protein A column, ensuring high purity and specificity.
Mature, recombinant, His-tagged Angola Marburgvirus Glycoprotein minus the transmembrane domain (AMARV rGPΔTM S2 BIP) is supplied as purified protein. AMARV rGPΔTM S2 BIP is produced in stably transfected Drosophilia Schneider 2 (S2) cells and is purified by FPLC.
Immunogen/ Target: Marburg glycoprotein minus transmembrane domain
Formulation & Storage: Store at -20°C for 2-3 weeks, -80°C for long-term
Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.
This antibody is intended for research use only, not for human, therapeutic, or diagnostic applications
Mature, recombinant, His-tagged Musoke Marburgvirus Glycoprotein minus the mucin and transmembrane domain (MMARV rGPΔmucΔTM) is supplied as a purified protein. MMARV rGPΔmucΔTM is produced in S2 cells and is purified by FPLC.
Immunogen/ Target: Marburg glycoprotein minus mucin domain
Formulation & Storage: Store at 4°C for 2-3 weeks, -80°C for long-term
Certificate of analysis: A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information.
This antibody is intended for research use only, not for human, therapeutic, or diagnostic applications
Recombinant Vesicular Stomatitis Virus pseudotyped MARV-Ci67 glycoprotein (rVSV pseudotyped MARV-Ci67 GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Marburg virus.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
Recombinant Vesicular Stomatitis Virus pseudotyped Marburg-Musoke glycoprotein (rVSV-ΔG MARV-Musoke GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Marburg virus.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
Recombinant Vesicular Stomatitis Virus pseudotyped Ravn virus glycoprotein (rVSV-ΔG RAVV GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Ravn virus.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, Lglutamine and Penicillin/Streptomycin. Store at -80°C.
Recombinant Vesicular Stomatitis Virus (rVSV) pseudotyped with Bundibugyo ebolavirus glycoprotein (rVSV-BDBV-GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Bundibugyo ebolavirus virus. Since the infectivity of pseudotyped virus is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, L-glutamine and Penicillin/Streptomycin. Store at -80°C.
Recombinant Vesicular Stomatitis Virus (rVSV) pseudotyped with Bundibugyo ebolavirus glycoprotein (rVSV-BDBV-GP) system in which the G protein of VSV has been deleted, replaced with firefly luciferase and used to produce VSV-pseudotyped virus containing the envelope glycoprotein of Bundibugyo ebolavirus virus. Since the infectivity of pseudotyped virus is restricted to a single round of replication, analyses of viral entry can be performed using just biosafety level 2 (BSL-2) containment.
Formulation & Storage: Supplied in EMEM™ (Gibco) supplemented with 1% Fetal Bovine Serum, L-glutamine and Penicillin/Streptomycin. Store at -80°C.
